Integra Lifesciences (IART) vs. NuVasive (NUVA) Financial Review

Integra Lifesciences (NASDAQ: IART) and NuVasive (NASDAQ:NUVA) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Valuation & Earnings

This table compares Integra Lifesciences and NuVasive’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Integra Lifesciences $992.08 million 3.68 $74.56 million $0.61 76.31
NuVasive $962.07 million 3.23 $37.14 million $1.19 51.27

Integra Lifesciences has higher revenue and earnings than NuVasive. NuVasive is trading at a lower price-to-earnings ratio than Integra Lifesciences, indicating that it is currently the more affordable of the two stocks.


This table compares Integra Lifesciences and NuVasive’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Integra Lifesciences 4.52% 16.35% 6.83%
NuVasive 6.36% 13.65% 6.17%

Institutional & Insider Ownership

87.6% of Integra Lifesciences shares are held by institutional investors. 21.5% of Integra Lifesciences shares are held by company insiders. Comparatively, 1.2% of NuVasive shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Integra Lifesciences has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, NuVasive has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Integra Lifesciences and NuVasive, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Integra Lifesciences 0 7 4 0 2.36
NuVasive 0 2 13 0 2.87

Integra Lifesciences currently has a consensus price target of $53.11, indicating a potential upside of 14.09%. NuVasive has a consensus price target of $71.64, indicating a potential upside of 17.43%. Given NuVasive’s stronger consensus rating and higher probable upside, analysts plainly believe NuVasive is more favorable than Integra Lifesciences.


Integra Lifesciences beats NuVasive on 8 of the 14 factors compared between the two stocks.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions. It sells products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care. It also sells regenerative technology products for treating acute wounds, such as burns, and chronic wounds, including diabetic foot ulcers and surgical tissue repair. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery.

NuVasive Company Profile

Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with's FREE daily email newsletter.

Leave a Reply